Physician profile
Sudhin Kanabar
NPI 1750373882
$5,321.20
in general payments reported to CMS, 2019-2025
34 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $308 · 2021: $554 · 2023: $291 · 2024: $1,429 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,597 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,597.23 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $546.51 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $434.72 | 2019-2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $422.80 | 2019-2025 | Rexulti, Nuedexta |
| Novartis Pharmaceuticals Corporation | $363.78 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $322.36 | 2023-2025 | Nuplazid |
| Lilly USA, LLC | $261.70 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Allergan, INC. | $260.73 | 2019-2020 | |
| Pfizer INC. | $222.17 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $210.95 | 2023-2025 | Epidiolex |
| Biogen, INC. | $198.69 | 2023-2025 | Vumerity, Skyclarys, Skyclarys |
| Alexion Pharmaceuticals, INC. | $191.79 | 2023-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $180.77 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Eli Lilly and Company | $175.00 | 2021 | |
| Abbvie INC. | $168.31 | 2021-2025 | |
| Neurelis, INC. | $143.96 | 2024-2025 | Valtoco |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $138.41 | 2019-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $116.20 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $111.90 | 2024-2025 | Xeomin, Inbrija |
| Acorda Therapeutics, INC | $107.00 | 2019 | |
| Amgen INC. | $102.57 | 2019-2025 | Uplizna |
| Livanova USA, INC. | $99.11 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Biohaven Pharmaceuticals, INC. | $65.58 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $57.04 | 2024-2025 | Wainua |
| Amneal Pharmaceuticals LLC | $54.95 | 2024-2025 | Rytary, Ongentys |
| Neurocrine Biosciences, INC. | $53.27 | 2024-2025 | Ingrezza |
| Ucb, INC. | $52.96 | 2025 | Fintepla, Briviact, Nayzilam |
| Alnylam Pharmaceuticals INC. | $52.00 | 2024 | Amvuttra |
| Eisai INC. | $45.68 | 2025 | |
| Ani Pharmaceuticals, INC. | $41.73 | 2025 | Purified Cortrophin Gel |
| Promius Pharma LLC | $29.15 | 2019 | |
| Springworks Therapeutics, INC. | $24.50 | 2025 | Gomekli |
| Tanabe Pharma America, INC. | $23.91 | 2024 | |
| Genzyme Corporation | $22.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.47 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhin Kanabar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.